297 Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis

Abstract

Dupilumab was previously shown to reduce thymus and activation-regulated chemokine (TARC/CCL17) and total IgE levels in multiple type 2 inflammatory diseases, including atopic dermatitis (AD). Here, we assess the effects of dupilumab treatment on these biomarkers of type 2 inflammation in children aged 6 months – < 6 years with moderate-to-severe AD. In LIBERTY AD INFANT/PRE-SCHOOL (NCT03346434 part B), a phase 3, double-blind trial, children aged ≥ 6 months – < 6 years with moderate-to-severe AD inadequately controlled with topical therapies were randomized 1:1 to subcutaneous dupilumab (200 mg if baseline weight ≥ 5 – < 15 kg, 300 mg if ≥ 15 – < 30 kg) or placebo every 4 weeks for 16 weeks.